Predict your next investment

Venture Capital
kearnyvp.com

See what CB Insights has to offer

Investments

59

Portfolio Exits

11

Funds

1

About Kearny Venture Partners

Kearny Venture Partners is a venture capital and incubation firm based in San Francisco, California that aims to invest across a range of company stages including seed, early, mid, and later stage investments. Kearny's investment focus is on the healthcare sector and typically invests between $2 and $8 million to start with the aim of investing $10 to $15 million per portfolio company over the life of the company.

Kearny Venture Partners Headquarter Location

88 Kearny Street

San Francisco, California, 94108-5532,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Kearny Venture Partners News

Aerpio Therapeutics Closes $22M Financing

Apr 23, 2014

Chromatin closes series E financing Aerpio Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it closed a $22M financing round led by new investor OrbiMed, with existing investors Novartis Venture Funds, Satter Investment Management, Kearny Venture Partners, Venture Investors, Triathlon Medical Ventures and Athenian Venture Partners. Proceeds will support expanded development of AKB-9778, a small molecule activator of Tie2, currently in a Phase 2 trial for the treatment of diabetic macular edema (DME), and the advancement of AKB-4924, a small-molecule HIF1 activator, into clinical development for inflammatory bowel disease (IBD). Chau Q. Khuong, Private Equity Partner at OrbiMed, will join Aerpio’s Board of Directors. "Aerpio's unique approach to activating Tie2 with AKB-9778 has demonstrated safety and efficacy in early clinical trials and holds great promise for treatment of DME and other retinal diseases, as well as unmet needs outside of ophthalmology,” said Mr. Khuong. “OrbiMed is pleased to support the expanded development of AKB-9778, as well as the Company’s promising HIF1 activator program. " "OrbiMed has an impressive track record of supporting both public and private companies as they bring innovative new medicines to market, and we are excited to have them join our investor syndicate," stated Joseph Gardner, PhD, President and CEO of Aerpio. Aerpio recently initiated a randomized, double-masked, double dummy, Phase 2 study designed to assess the safety and efficacy of AKB-9778 administered over three months as monotherapy and as an adjunct with ranibizumab in subjects with DME. The primary endpoints of the study are change from baseline in visual acuity and change from baseline in central retinal thickness. Additionally, Aerpio is prioritizing further therapeutic opportunities for AKB-9778 and expects to initiate development in a second target indication before year end. With this financing, Aerpio will also progress a second pipeline candidate, AKB-4924, and activator of HIF1, into clinical development. HIF1 is critical for the regulation of innate immune responses and maintenance of epithelial barrier function, particularly in the gut and skin. HIF1 activators represent a promising new class of drugs with potential for potent and specific modulation of innate immunity. AKB-4924 has demonstrated robust activity in preclinical models of ulcerative colitis and Crohn's disease. About AKB-9778 AKB‐9778 is a first-in-class small molecule that works by inhibiting the human protein tyrosine phosphatase β (HPTPβ) enzyme, which acts as a negative regulator of the Tie2 receptor. By inhibiting this negative regulator, Tie2 signaling is restored, overcoming the effects of the Ang2‐induced vascular destabilization. Aerpio is currently focusing development of its lead candidate, AKB‐9778, in diabetic macular edema (DME), however, Tie2 activators have potential utility in a range of important clinical indications. In a Phase 1b/2a study in DME patients, AKB-9778 was well tolerated throughout 28 days of dosing, with evidence of disease improvement in some patients. A Phase 2 study to confirm efficacy of AKB-9778 alone and in combination with ranibizumab in patients with DME is currently ongoing. About Aerpio Therapeutics Aerpio Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. Aerpio is a leader in the development of small molecule drugs based on Tie2 activation and the stabilization of hypoxia-inducible factor 1α (HIF‐1α). The Company’s lead program, AKB‐9778, is a first‐in‐class stabilizer of the Tie2 pathway and is in clinical development for diabetic macular edema. More information is available at www.aerpio.com . About OrbiMed OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector with approximately $10 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies on a worldwide basis, from venture capital start-ups to large multinational companies. OrbiMed's team includes over 60 experienced professionals with offices in New York, San Francisco, Shanghai, Mumbai and Herzliya. OrbiMed manages a series of private equity funds, public equity funds, royalty and debt funds, and other investment vehicles. Aerpio Therapeutics, Inc.

Kearny Venture Partners Investments

59 Investments

Kearny Venture Partners has made 59 investments. Their latest investment was in PROCEPT BioRobotics as part of their Series G on June 6, 2021.

CBI Logo

Kearny Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/17/2021

Series G

PROCEPT BioRobotics

$85M

No

6

12/22/2020

Unattributed VC - III

Episode Solutions

$1.62M

No

1

10/23/2020

Unattributed VC - II

Colors Living Produce

$5M

No

1

8/14/2020

Series F

Subscribe to see more

$99M

Subscribe to see more

10

6/8/2020

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/17/2021

12/22/2020

10/23/2020

8/14/2020

6/8/2020

Round

Series G

Unattributed VC - III

Unattributed VC - II

Series F

Unattributed VC

Company

PROCEPT BioRobotics

Episode Solutions

Colors Living Produce

Subscribe to see more

Subscribe to see more

Amount

$85M

$1.62M

$5M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

1

1

10

10

Kearny Venture Partners Portfolio Exits

11 Portfolio Exits

Kearny Venture Partners has 11 portfolio exits. Their latest portfolio exit was PROCEPT BioRobotics on September 15, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/15/2021

IPO

$99M

Public

3

6/30/2021

IPO

$99M

Public

12

1/16/2019

Acquired

$99M

1

3/16/2017

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

7/24/2015

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/15/2021

6/30/2021

1/16/2019

3/16/2017

7/24/2015

Exit

IPO

IPO

Acquired

Reverse Merger

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

3

12

1

10

10

Kearny Venture Partners Fund History

1 Fund History

Kearny Venture Partners has 1 fund, including Kearny Venture Partners LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/31/2008

Kearny Venture Partners LP

Early-Stage Venture Capital

Closed

$100M

1

Closing Date

3/31/2008

Fund

Kearny Venture Partners LP

Fund Type

Early-Stage Venture Capital

Status

Closed

Amount

$100M

Sources

1

Kearny Venture Partners Team

4 Team Members

Kearny Venture Partners has 4 team members, including current Chief Financial Officer, Andrew I. Jensen.

Name

Work History

Title

Status

Andrew I. Jensen

Gryphon Investors, Sanderling Ventures, and Andersen

Chief Financial Officer

Current

James M. Shapiro

Managing Director

Current

Anupam Dalal

General Partner

Current

Richard C. Spalding

General Partner

Current

Name

Andrew I. Jensen

James M. Shapiro

Anupam Dalal

Richard C. Spalding

Work History

Gryphon Investors, Sanderling Ventures, and Andersen

Title

Chief Financial Officer

Managing Director

General Partner

General Partner

Status

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.